ストックスクリーナーアプリを入手
11.19
4.28%
-0.50
アフターアワーズ：
11.41
0.22
+1.97%
Delcath Systems Inc (DCTH) 最新ニュース
Delcath Systems, Inc. - MLQ.ai
Delcath Systems, Inc. Stock 12‑Month Price Target Cut to $20.83, Implies 95% Upside - TradingView
European cancer guidelines add Delcath liver therapy for eye melanoma - Stock Titan
Delcath therapy included in European uveal melanoma guidelines - Investing.com
FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC - Quantisnow
(DCTH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Abbott’s $21bn Bet on Exact Sciences Takes Center Stage at ASCO 2026 - Citeline News & Insights
Delcath Systems Q1 2026 Earnings: Narrowed Loss Surprises, Stock AdvancesCore Business Growth - newsline.com
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - BioSpace
Delcath Systems Publishes Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - Moomoo
Q3 2025 Delcath Systems Inc Earnings Call Transcript - GuruFocus
Q1 2026 Delcath Systems Inc Earnings Call Transcript - GuruFocus
DCTH Q1 2026 Earnings: Narrower-Than-Expected Loss Bolstered by Cost DisciplineEarnings Beat Alert - The Legal Advocate
Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued - GuruFocus
Delcath Systems announces inducement grants - Medical Buyer
How (DCTH) Movements Inform Risk Allocation Models - Stock Traders Daily
Implied volatility surging for Delcath Systems stock options - MSN
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Daily Tribune News
Delcath Systems announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Delcath hires receive 24,500 stock units over 3 years - Stock Titan
Dental EconomicsDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Delcath Systems (DCTH) director receives grant of 22,500 stock options at $11.61 - Stock Titan
Delcath Systems (NASDAQ: DCTH) director receives 22,500 stock options at $11.61 strike - Stock Titan
Delcath Systems (DCTH) director awarded 22,500 stock options at $11.61 - Stock Titan
Director at Delcath (NASDAQ: DCTH) awarded 22,500 stock options - Stock Titan
Delcath (DCTH) awards director 22,500 options at $11.61 strike - Stock Titan
Delcath Systems, Inc. 8-K Filing May 13, 2026 – Company Information, Equity Incentive Plan, and SEC Compliance 212 - Minichart
Delcath Shareholders Approve Expanded Equity Plan and Governance - TipRanks
Delcath Systems shareholders approve equity plan amendment and board elections - Investing.com Nigeria
Delcath Systems shareholders approve equity plan amendment and board elections By Investing.com - Investing.com South Africa
Delcath (NASDAQ: DCTH) approves 1.8M-share boost to 2020 equity plan - Stock Titan
Earnings call transcript: Delcath Systems Q1 2026 beats EPS forecast, stock rises - Investing.com Nigeria
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference - Yahoo Finance
TradingKey - TradingKey
Delcath Systems Q1 2026: -$0.03 EPS Tops Estimates — Deep Dive - AlphaStreet
Tangible book value per share of Delcath Systems, Inc. – SWB:DV3R - TradingView
Delcath Systems Balances Growth with Rising Costs - The Globe and Mail
MSN Money - MSN
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Delcath Systems, Inc. (NASDAQ:DCTH) Q1 2026 Earnings Call Transcript - Insider Monkey
Delcath Systems (NASDAQ:DCTH) Announces Quarterly Earnings Results - MarketBeat
Delcath Systems, Inc. (DCTH) Stock Analysis: Aiming for an 89.80% Upside in the Medical Device Sector - DirectorsTalk Interviews
Uveal Melanoma Treatment Market is expected to Hit US$ 2.7 - openPR.com
Delcath Systems Reports First Quarter 2026 Results and Business Highlights - BioSpace
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 - BioSpace
Number of shareholders of Delcath Systems, Inc. – DUS:DV3R - TradingView
Delcath Systems, Inc. (DCTH) reports Q1 loss, misses revenue estimates - MSN
Delcath Systems Q1 Earnings Call Highlights - MarketBeat
Delcath Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
1.63%
大文字化:
|
ボリューム (24 時間):